Kite, Pfizer to conduct combo trial of Yescarta and utomilumab

The Kite Pharma Inc. unit of Gilead Sciences Inc. (NASDAQ:GILD) partnered with Pfizer Inc. (NYSE:PFE) to conduct a Phase I/II

Read the full 201 word article

User Sign In